
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: March 25, 2025
The persistently high mortality rates associated with cancer underscore the imperative need for innovative, efficacious, and safer therapeutic agents, as well a more nuanced understanding of tumor biology. Patient-derived organoids (PDOs) have emerged innovative preclinical models significant translational potential, capable accurately recapitulating structural, functional, heterogeneous characteristics primary tumors. When integrated cutting-edge genomic tools such CRISPR, PDOs provide powerful platform identifying driver genes novel targets. This comprehensive review delves into recent advancements in CRISPR-mediated functional screens leveraging across diverse types, highlighting their pivotal role high-throughput genomics microenvironment (TME) modeling. Furthermore, this highlights synergistic potential integrating CRISPR immunotherapy, focusing on uncovering immune evasion mechanisms improving efficacy immunotherapeutic approaches. Together, these technologies offer promise advancing precision oncology.
Language: Английский